Overview:
HPV Detection Genotyping PanelIntroduction: The Human Papillomavirus Detection Genotyping Panel is a diagnostic tool designed to detect and genotype HPV using cervical swabs. In India, cervical cancer is the second leading cancer in women (~120,000 new cases/year, ~70,000 deaths), with high-risk HPV (16/18) responsible for ~70 percent of cases; persistent infection leads to precancerous lesions. High morbidity from under-testing in rural/low-SES women, limited screening programs, delayed HPV detection leading to late-stage cancer. Per oncology practices aligned with ICMR, National Cancer Control Programme, and FOGSI guidelines, the test employs PCR for HPV DNA, high-risk genotypes, and low-risk genotypes over 1-2 days with high accuracy, valuable for primary screening and triage of abnormal Pap. This diagnostic falls under HPV screening and targets women >30 years or with abnormal cytology, addressing accurate detection to guide colposcopy, vaccination counseling, or follow-up. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise HPV profiling and reducing cervical cancer burden. Its cervical swab-based approach ensures reliable genotyping.
Other Names: HPV Geno Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.
Historical Milestone: HPV DNA genotyping standard since 2000s; in India, expanding in screening programs.
Purpose: The test assesses 3 parameters including HPV DNA to guide cervical cancer screening, detect/genotype HPV, inform colposcopy.
Test Parameters: 1. HPV DNA, 2. High-Risk Genotypes, 3. Low-Risk Genotypes.
Pretest Condition: No fasting required; patients should be screened for cervical cancer.
Specimen: 1 cervical swab in transport medium, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on Pap smear, vaccination.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected HPV including cancer, benefits of screening, and minimal discomfort from swab collection.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive high-risk HPV indicates increased cancer risk, necessitating specialist input.
Specialist Consultation: Gynecologists or oncologists should be consulted for management.
Additional Supporting Tests: Pap smear, colposcopy for confirmation.
Test Limitations: Detects DNA only; comprehensive approach required.
References: Indian Journal of Medical Oncology 2024, Cervical Cancer Studies India 2023.
